Barclays PLC Has $1.89 Million Stock Position in Artivion, Inc. (NYSE:AORT)

Barclays PLC increased its stake in shares of Artivion, Inc. (NYSE:AORT - Free Report) by 346.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 70,877 shares of the company's stock after buying an additional 54,996 shares during the quarter. Barclays PLC owned 0.17% of Artivion worth $1,888,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Artivion by 58.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company's stock worth $9,074,000 after buying an additional 125,668 shares in the last quarter. Perceptive Advisors LLC grew its position in Artivion by 4.7% during the 2nd quarter. Perceptive Advisors LLC now owns 2,793,703 shares of the company's stock worth $71,658,000 after acquiring an additional 124,725 shares during the last quarter. Sio Capital Management LLC acquired a new stake in Artivion during the 3rd quarter valued at $3,226,000. Wellington Management Group LLP raised its position in Artivion by 2.9% in the 3rd quarter. Wellington Management Group LLP now owns 1,656,264 shares of the company's stock valued at $44,090,000 after purchasing an additional 46,267 shares during the last quarter. Finally, Walleye Capital LLC acquired a new position in Artivion in the third quarter worth $960,000. 86.37% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Artivion news, CAO Amy Horton sold 12,430 shares of the firm's stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total transaction of $325,417.40. Following the transaction, the chief accounting officer now owns 139,989 shares in the company, valued at approximately $3,664,912.02. This trade represents a 8.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Jean F. Holloway sold 8,070 shares of the company's stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $30.12, for a total value of $243,068.40. Following the completion of the sale, the senior vice president now directly owns 153,862 shares of the company's stock, valued at approximately $4,634,323.44. This trade represents a 4.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 32,447 shares of company stock valued at $925,424 over the last ninety days. Insiders own 8.10% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Oppenheimer lifted their price target on Artivion from $30.00 to $32.00 and gave the company an "outperform" rating in a report on Friday, November 8th. Stifel Nicolaus boosted their target price on shares of Artivion from $28.00 to $30.00 and gave the stock a "buy" rating in a research note on Friday, September 13th. Needham & Company LLC reiterated a "buy" rating and set a $34.00 target price on shares of Artivion in a research report on Monday, December 9th. Finally, JMP Securities reissued a "market outperform" rating and issued a $33.00 price target on shares of Artivion in a report on Tuesday, December 10th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Artivion has a consensus rating of "Buy" and an average price target of $31.80.

Artivion Trading Down 1.2 %

Artivion stock traded down $0.34 during trading hours on Friday, reaching $29.00. 147,676 shares of the company's stock traded hands, compared to its average volume of 228,003. Artivion, Inc. has a fifty-two week low of $16.48 and a fifty-two week high of $30.45. The firm's 50 day moving average is $28.15 and its 200-day moving average is $26.51. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88. The firm has a market capitalization of $1.22 billion, a price-to-earnings ratio of -1,450.00 and a beta of 1.75.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.